(Q40072113)

17 September 2017

Neurocognitive testing in late-onset Tay-Sachs disease: a pilot study (English)

1 reference

17 September 2017

1 reference

D Elstein

1

1 reference

17 September 2017

G M Doniger

2

1 reference

17 September 2017

E Simon

3

1 reference

17 September 2017

I Korn-Lubetzki

4

1 reference

17 September 2017

R Navon

5

1 reference

17 September 2017

A Zimran

6

1 reference

17 September 2017

30 May 2008

1 reference

Journal of Inherited Metabolic Disease

17 September 2017

1 reference

17 September 2017

31

1 reference

17 September 2017

4

1 reference

17 September 2017

518-523

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-008-0884-z

17 September 2017

0 references

cites work

Neuropsychological assessment of patients with late onset GM2 gangliosidosis.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10545-008-0884-Z

Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients.

21 January 2018

1 reference

12 December 2020

Late onset GM2-gangliosidosis. Clinical, pathological, and biochemical studies on 8 patients

1 reference

12 December 2020

Validity of the Mindstreams computerized cognitive battery for mild cognitive impairment.

1 reference

12 December 2020

Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin

1 reference

12 December 2020

Inherited lipid storage diseases of the central nervous system

1 reference

12 December 2020

Progressive cerebellar ataxia, proximal neurogenic weakness and ocular motor disturbances: hexosaminidase A deficiency with late clinical onset in four siblings

1 reference

12 December 2020

Adult onset supranuclear ophthalmoplegia, cerebellar ataxia, and neurogenic proximal muscle weakness in a brother and sister: another hexosaminidase A deficiency syndrome

1 reference

12 December 2020

Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction

1 reference

12 December 2020

Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations

1 reference

12 December 2020

The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis

1 reference

12 December 2020

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement

1 reference

12 December 2020

10.1007/S10545-008-0884-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

17 September 2017

0 references

1 reference